Gynecologic Malignancies


Share

Program Content

Activities

  • ASCO to Clinic: Gynecologic Cancer
    Conference to Clinic: Gynecologic Cancer
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 20, 2023

  • Conference to Clinic: Gynecologic Cancers
    Conference to Clinic: Expert Analysis of the Top Gynecologic Cancer Abstracts From the 2023 Oncology Meeting in Chicago
    Video
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 29, 2023

    Expires: June 28, 2024

  • EA: Top Gyn Cancer Abstracts
    Conference to Clinic: Expert Analysis of the Top Gynecologic Cancer Studies From the 2023 Oncology Meeting in Chicago
    Text Module
    Congratulations: You achieved a completion on 04/09/2022

    Released: August 03, 2023

    Expires: August 02, 2024

Activities

RUBY Dostarlimab + CT
ENGOT-EN6-NSGO/GOG3031/RUBY: Outcomes by BICR With Addition of Dostarlimab to Carboplatin/Paclitaxel for Advanced or Recurrent Endometrial Cancer
Capsule Summary
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 09, 2023

KEYNOTE-826 Final Analysis
KEYNOTE-826: Final OS Analysis of Pembrolizumab + Chemotherapy vs Placebo + Chemotherapy in Persistent, Recurrent, or Metastatic Cervical Cancer
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 05, 2023

RUBY: HRQoL With Dostarlimab + CP in EC
ENGOT-EN6-NSGO/GOG-3031/RUBY: PROs With Addition of Dostarlimab to  Carboplatin/Paclitaxel for Advanced or Recurrent Endometrial Cancer
Capsule Summary
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 09, 2023

MIRASOL
MIRASOL: Mirvetuximab Soravtansine vs Investigator’s Choice of Chemotherapy in FRα-High Expression, Platinum-Resistant Advanced Ovarian, Primary Peritoneal, or Fallopian Tube Cancers
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 05, 2023

DUO-O
DUO-O: First-line CT + Bevacizumab ± Durvalumab Followed by Maintenance Bevacizumab ± Durvalumab With or Without Olaparib in Newly Diagnosed Advanced Ovarian Cancer Without Tumor BRCA Mutation
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 07, 2023

SHAPE
SHAPE: Radical Hysterectomy and Pelvic Node Dissection vs Simple Hysterectomy and Pelvic Node Dissection in Low-Risk Early-Stage Cervical Cancer
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 07, 2023

Faculty

cover img faculity

Lauren Prescott, MD, MPH

Associate Professor of Gynecologic Oncology
Department of Obstetrics and Gynecology
Vanderbilt University Medical Center
Nashville, Tennessee

cover img faculity

Ritu Salani, MD, MBA

Director, Division of Gynecologic Oncology
Professor, Department of Obstetrics and Gynecology
David Geffen School of Medicine at UCLA
Los Angeles, California

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

Supported by educational grants from AstraZeneca, GSK, and Merck Sharp & Dohme Corp.

AstraZeneca

GSK

Merck Sharp & Dohme Corp.